Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCKBR | P32239 | 2/20 | 0.42 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.41 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.35 |
| ▸ | HRH2 | P25021 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.33 |
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3957829 | 0.85 | CCKBR (0.40) | CCKBRPAX8HRH2OPRM1HTR2B | |
| SCHEMBL3961341 | 0.85 | CCKBR (0.40) | CCKBRPAX8HRH2OPRM1HTR2B | |
| SCHEMBL1688324 | 0.85 | CCKBR (0.40) | CCKBRPAX8HRH2OPRM1HTR2B | |
| SCHEMBL6630128 | 0.84 | CCKBR (0.42) | CCKBRPAX8HRH2OPRM1HTR2B | |
| SCHEMBL14610590 | 0.82 | CCKBR (0.39) | CCKBRPAX8OPRM1 | |
| SCHEMBL31366241 | 0.82 | CCKBR (0.39) | CCKBRPAX8OPRM1 | |
| SCHEMBL6332268 | 0.81 | BCHE (0.44) | CCKBRPAX8CREBBP | |
| SCHEMBL3692425 | 0.80 | HTR2A (0.42) | CCKBRHRH2OPRM1HTR2BAKT1 | |
| SCHEMBL1118519 | 0.80 | CCKBR (0.42) | CCKBRPAX8CREBBPHRH2OPRM1 | |
| SCHEMBL12013752 | 0.80 | CCKBR (0.42) | CCKBRPAX8CREBBPHRH2OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612424-B2 | HPK1 inhibitors and uses thereof | REGOR PHARMACEUTICALS, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| CN-114555585-B | HPK1 inhibitors and uses thereof | 锐格药业公司 | 2025-02-11 | — | — | CN | disclosed |
| EP-3939981-B1 | FUSED THIAZOLOPYRIMIDINE DERIVATIVES AS MNKS INHIBITORS | LIFEARC (GB) | 2024-04-03 | — | — | EP | disclosed |
| CN-114315796-B | Compounds used as HPK1 kinase inhibitor, preparation method and application thereof | 中国药科大学 | 2024-03-26 | — | — | CN | disclosed |
| US-20230150978-A1 | QUINAZOLINONE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER | ENYO PHARMA (FR) | 2023-05-18 | — | — | US | disclosed |
| EP-4126847-A1 | QUINAZOLINONE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER | ENYO Pharma (FR) | 2023-02-08 | — | — | EP | disclosed |
| US-20220389037-A1 | HPK1 INHIBITORS AND USES THEREOF | REGOR PHARMACEUTICALS, INC. | 2022-12-08 | — | — | US | disclosed |
| US-20220389037-A1 | HPK1 INHIBITORS AND USES THEREOF | REGOR PHARMACEUTICALS, INC. | 2022-12-08 | — | — | US | disclosed |
| CN-108495855-B | Fused thiazolopyrimidine derivatives as MNK inhibitors | 生命弧度公司 | 2022-05-31 | — | — | CN | disclosed |
| CN-114555585-A | HPK1 inhibitors and uses thereof | 上海齐鲁锐格医药研发有限公司 | 2022-05-27 | — | — | CN | disclosed |
| EP-2225223-A2 | ORGANIC COMPOUNDS | Boehringer Ingelheim International GmbH (DE) | 2010-09-08 | — | — | EP | disclosed |
| WO-2009065920-A2 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-05-28 | — | — | WO | disclosed |
| WO-2009065920-A2 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-05-28 | — | — | WO | disclosed |
| WO-2009065919-A2 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-05-28 | — | — | WO | disclosed |
| WO-2009065919-A2 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-05-28 | — | — | WO | disclosed |
| CN-101304989-A | Carbocyclic fused cyclic amines as inhibitors of the coagulation factor XA | HOFFMANN LA ROCHE (CH) | 2008-11-12 | — | — | CN | disclosed |
| EP-1948639-A2 | NOVEL CARBOCYCLIC FUSED CYCLIC AMINES | F. Hoffmann-la Roche AG (CH) | 2008-07-30 | — | — | EP | disclosed |
| WO-2007054453-A2 | CARBOCYCLIC FUSED CYCLIC AMINES AS INHIBITORS OF THE COAGULATION FACTOR XA | F. HOFFMANN-LA ROCHE AG (CH) | 2007-05-18 | — | — | WO | disclosed |
| US-20070112012-A1 | Carbocyclic fused cyclic amines | F. HOFFMANN-LA ROCHE AG (CH) | 2007-05-17 | — | — | US | disclosed |
| US-6909006-B1 | Cyclopropylindole derivatives | SPIROGEN LIMITED (GB) | 2005-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112012-A1 | Carbocyclic fused cyclic amines | F12, F11, F2 | CCKBR 119/4885PAX8 3601/4885CREBBP 3800/4885 |
| US-12612424-B2 | HPK1 inhibitors and uses thereof | NEK11, NEK1, CSNK1A1 | CCKBR 2962/4885PAX8 3075/4885CREBBP 1801/4885 |
| US-20230150978-A1 | QUINAZOLINONE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER | NQO2, NQO1, NDUFV2 | CCKBR 1691/4885PAX8 3302/4885CREBBP 2481/4885 |
| US-20220389037-A1 | HPK1 INHIBITORS AND USES THEREOF | HIPK1, SIK1, PGK1 | CCKBR 4089/4885PAX8 2291/4885CREBBP 1664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.